Changchun High-tech: Subsidiary receives the first payment of USD 70 million for the GenSci098 project.

Changchun Hi-Tech announced that after its holding subsidiary, Jinsai Pharmaceutical's sub-company Saizeng Medical signed an exclusive license agreement with Yarrow for the GenSci098 injection project, it received a one-time payment of $70 million from Yarrow on January 14, 2026. The actual amount received needs to deduct relevant taxes and fees. The agreement was signed on December 15, 2025, and Saizeng Medical authorized Yarrow with global exclusive development rights for GenSci098 injection except for the Greater China region. GenSci098 injection is independently developed by Jinsai Pharmaceutical and has been approved for clinical trials in China and the United States. This payment will increase the company's cash reserves, support pipeline research and development, and internationalization strategy.